Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co FCF Margin % Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Double-Crane Pharmaceutical Co FCF Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a FCF Margin % of 11.13% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. This is near median its historical median of 11.46. Over the past decade, China Resources Double-Crane Pharmaceutical Co's FCF Margin % has ranged from 7.61 to 16.07. According to the industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #337 out of 959 companies in the Drug Manufacturers industry, placing it in the top 35.1%.
Is China Resources Double-Crane Pharmaceutical Co's FCF Margin % too high?
China Resources Double-Crane Pharmaceutical Co's current FCF Margin % of 11.13% is near median its 10-year median of 11.46. Over the past 10 years, this metric has ranged from a low of 7.61 to a high of 16.07. The Drug Manufacturers industry median FCF Margin % is 2.45. China Resources Double-Crane Pharmaceutical Co's value of 11.13% is 354.3% above this industry median. Based on the distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #337 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #337 out of 959 companies for FCF Margin %. This puts China Resources Double-Crane Pharmaceutical Co in the upper half of its industry. The industry median FCF Margin % is 2.45. China Resources Double-Crane Pharmaceutical Co's value of 11.13% is 354.3% above this benchmark. Historically, China Resources Double-Crane Pharmaceutical Co's own FCF Margin % has ranged from 7.61 to 16.07 over the past decade. While the company's 10-year median is 11.46 vs. the industry median of 2.45, China Resources Double-Crane Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current FCF Margin % of 11.13% is 354.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current FCF Margin % is 11.13%, which is near median its own 10-year median of 11.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.69, compared to a current price of ¥15.67 — trading 16.2% below its estimated fair value. The current FCF Margin % is 11.13%, which is near median its 10-year median of 11.46 and 354.3% above the Drug Manufacturers industry median of 2.45. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current FCF Margin % is 11.13% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥15.67 is trading 16.2% below its estimated GF Value™ of ¥18.69.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600062:
FCF Margin %: 11.13% (near median its 10-year median of 11.46)
GF Value™: ¥18.69 vs. price of ¥15.67 (16.2% below fair value)
Industry Position: 354.3% above the Drug Manufacturers median (#337 of 959)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
94GF Score
Get the complete analysis for SHSE:600062
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
